THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Ekambar R. Kandimalla et al)	Examiner: TBA
Serial No.:	09/965,116)	Art Unit: 1632
Filed:	September 26, 2001)	
For: Modulation of Immunostimulatory Activity of Immunostimulatory Modified Oligodeoxynucleotide Phosphorothioate Analogs by Positional Chemical Changes))))	
Attorney Docket No. HYZ-479CP (47508.577))	

TRANSMITTAL LETTER

BOX SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed are the following for appropriate action:

- 1. Reply;
- 2. Statement Under 37 C.F.R. §1.82(f);
- Written copy of Sequence Listing information; 3.
- Diskette containing Sequence Listing information; 4.
- Copy of Notice to Comply with Requirements for Patent Applications Containing 5. Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and
- 6. Return postcard.

No fees are believed to be due in connection with the filing of this Sequence Listing. However, the Commissioner is hereby authorized to debit Deposit Account No. 08-0219 for any required fee necessary to maintain the pendency of this application.

Respectfully submitted,

HALE AND DORR LLP 60 State Street Boston, MA 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile)

Registration No. 33,523

and-house Kern

Ann-Louise Kerner, Ph.D.

Registration No. 33 523

EXPRESS MAIL LABEL NO. EV 038247030US

march 8, 2002



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/965,116

09/26/2001

Ekambar R. Kandimalla

HYZ-479CP (47508.577)

23483 HALE AND DORR, LLP 60 STATE STREET BOSTON, MA 02109 CONFIRMATION NO. 3956
FORMALITIES LETTER
OC000000007293688

Date Mailed: 01/10/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE